Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ARQ 531 is a reversible inhibitor of wild type and C481S-mutant BTK. Here, Jennifer Woyach, MD, of the Ohio State University College of Medicine, Columbus, OH, tells us about the promising preliminary data from the Phase I dose escalation study (NCT03162536) across a variety of B-cell malignancies.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.